Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Liberia

NCT06300970 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT06300970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06300970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Liberia
Lead sponsor
Centers for Disease Control and Prevention
Phase
Phase 4
Overall status
Completed
Start date
August 9, 2022
Completion date
August 16, 2023
Enrollment
352 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, plasmodium falciparum, uncomplicated malaria